video1.0<iframe src="https://www.loom.com/embed/1879b4e38e0549a2ac5424d74bbdf442" frameborder="0" width="1920" height="1440" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>14401920Loomhttps://www.loom.com14401920https://cdn.loom.com/sessions/thumbnails/1879b4e38e0549a2ac5424d74bbdf442-2b7fcac5c413f581.gif1799.998In this presentation, I discussed the challenges and strategies for treating babesiosis, particularly in immunocompromised patients. I shared two case studies highlighting the complexities of managing persistent babesiosis and the importance of drug dosing and scheduling. Notably, I emphasized the potential of repurposing malaria drugs, such as atovaquone and azithromycin, for effective treatment. I also presented data on the pharmacodynamics of these drugs, advocating for a higher dosing regimen to improve outcomes. I encourage you to consider these insights in your clinical practice and remain vigilant about the dosing strategies we employ.